Innopeutics

Innopeutics is a South Korean biotechnology company specializing in the development of next-generation gene therapies for central nervous system (CNS) disorders. The company leverages its proprietary Adeno-Associated Virus (AAV) vector platform to deliver therapeutic genes, such as Hepatocyte Growth Factor (HGF), to promote neuroregeneration and neuroprotection. Its lead pipeline candidates target chronic and debilitating conditions including spinal cord injury and Alzheimer’s disease, aiming to restore neurological function where conventional treatments have failed. Innopeutics is currently advancing its lead programs through the pre-clinical stage with the goal of entering global clinical trials.